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Abstract
Background There is limited knowledge of the effective-
ness and safety profile of cinacalcet in pediatric patients
with secondary hyperparathyroidism (sHPT) treated with
dialysis.
Methods This was an open-label, single-dose study conducted
on 12 pediatric subjects with chronic kidney disease treated
with dialysis. Subjects were stratified by four age cohorts and
given a single 15-mg oral dose of cinacalcet. Multiple blood
samples were collected up to 72 h post-dose for the assessment
of serum calcium (Ca), serum intact parathyroid hormone
(iPTH), and plasma cinacalcet concentrations.
Results Overall, cinacalcet was well tolerated with no seri-
ous adverse events. Mean (standard deviation) percentage
change in serum Ca over the first 12 h post-dose was
−2.93 % (5.70 %) with a nadir of −4.34 % (6.04 %) at
8 h; Ca values returned to baseline by 48 h post-dose. Mean
percentage change in iPTH over the first 12 h post-dose was
57.94 % (71.82 %) with a nadir of −35.65 % (55.82 %) at
2 h. There was an inverse relationship between peak serum
Ca concentration and body surface area (BSA) (r200.41),
although no relationship was found between area under the
curve and age or BSA.
Conclusions These data support future analysis to deter-
mine the therapeutic starting dose of cinacalcet for pediatric
patients with sHPT on dialysis.
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Introduction
Pediatric and adult patients with chronic kidney disease
(CKD) are subject to a unique constellation of signs and
symptoms that affect bone and mineral metabolism, termed
collectively, CKD–mineral and bone disorders (CKD–MBD).
Part of the biochemical picture in CKD–MBD includes ele-
vated blood levels of fibroblast growth factor 23 (FGF23) and
reduced blood levels of calcitriol. Markedly high levels of
FGF23 in combination with parameters of abnormal mineral
metabolism are associated with progressive increases in serum
intact parathyroid hormone (PTH), referred to as secondary
hyperparathyroidism (sHPT).
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The hyperphosphatemia and hypocalcemia seen in CKD–
MBD worsens sHPT, a disease associated with bone disease
as well as systemic cardiovascular and cutaneous toxicities
[1]. Although therapies for sHPT include lowering serum
phosphorus (P) through dietary restrictions and the use of
phosphate binders, supplementation of calcium (Ca), vita-
min D analogs, and parathyroidectomy [2], these options
have significant limitations associated to dietary restrictions,
medication non-adherence, as well as adverse reactions. In
patients with end-stage renal disease (ESRD), vitamin D
sterols are effective in the short term in lowering the serum
concentration of PTH through both direct and indirect
mechanisms [3, 4]. However, the efficacy of vitamin D
sterols in suppressing iPTH may be reduced due to their
potential to raise serum Ca and P levels.
The calcimimetic Sensipar®/Mimpara® (cinacalcet;
Amgen, Thousand Oaks, CA) is an addition to existing dial-
ysis therapies, designed to treat sHPT [5–8]. Cinacalcet
belongs to a family of small organic allosteric activators of
the G-protein-coupled calcium sensing receptor (CaSR) in the
parathyroid glands and other tissues [9]. It increases the sen-
sitivity of extracellular CaSR to extracellular Ca. Activation of
CaSR decreases both the synthesis and secretion of PTH [10]
and subsequently decreases serum Ca and P, as well as the Ca
× P product in adult dialysis patients. In such patients with
sHPT on hemodialysis, cinacalcet has been shown to be
effective in lowering PTH levels to clinically acceptable levels
that satisfy biochemical target ranges defined by the Kidney
Disease Outcomes Quality Initiative (K-DOQI)TM for disease
management [5, 7, 8, 11–13]. Cinacalcet doses are adjusted
based on response to PTH levels.
Approximately 80 % of pediatric patients with CKD and
on dialysis are treated for renal osteodystrophy. There is
little evidence that parathyroid gland function differs in
children and adolescents with ESRD compared to adults
[14]. Thus, there is reason to believe that pediatric dialysis
patients with sHPT will also respond to treatment with
cinacalcet. To date, there are no published randomized con-
trolled studies evaluating the safety and efficacy of cinacal-
cet in the pediatric dialysis population. However, several
retrospective observational studies have demonstrated that
PTH levels decrease following the initiation of cinacalcet
treatment, including that of Silverstein et al. [15] who found
decreased PTH levels within the first month of initiating
cinacalcet treatment, with no change in Ca, P, or Ca × P after
3 months in nine pediatric dialysis patients, while Muscheites
et al. [16] reported statistically significant and clinically rel-
evant decreases for PTH, Ca, P, and Ca × P within a 4-week
treatment period. Although these findings are consistent with
the literature on cinacalcet in the adult populations [17], both
studies were based on adult dosing guidelines and illustrate
the need to further investigate cinacalcet use prospectively in
the pediatric dialysis population.
Limited therapeutic options highlight an unmet need for a
more effective therapy for sHPT in pediatric patients on
dialysis. Thus, the study reported here was designed to
evaluate the safety, tolerability, pharmacokinetics, and phar-
macodynamics of a 15-mg dose of cinacalcet in pediatric
subjects with sHPT treated with hemodialysis.
Methods
This was a single-dose, open-label study to evaluate the
safety, tolerability, pharmacokinetics, and pharmacodynam-
ics of cinacalcet in pediatric subjects with CKD on dialysis.
The ethics committees of each study center reviewed and
approved the study protocol and the consent forms prior to
the investigators enrolling subjects. Twelve subjects were
enrolled, and all subjects continued their regular therapy
for management of sHPT (e.g., phosphate binder, vitamin
D sterol). Oral or intravenous Ca therapy and alteration
of the dialysate calcium concentration was allowed
for serum Ca <1.87 mmol/L (7.5 mg/dL) or signs or
symptoms of hypocalcemia subsequent to the study drug
administration.
Seven girls and five boys aged 6–17 years on dialysis for
at least 1 month at the time of screening were enrolled in the
study. Written informed consent was obtained from the
parent or guardian for all subjects; additionally, written
assent was obtained from subjects ≥12 years of age. Sub-
jects were eligible to participate if they had serum Ca level
of ≥8.4 mg/dL at the time of the baseline visit and had not
received any cinacalcet therapy for at least 2 weeks before
Day 1 dosing.
To ensure subjects were enrolled across the entire age range
of 6–17 years, three subjects were required to be enrolled into
each of the following age-cohorts: 6–8, 9–11, 12–14, and 15–
17 years. After a minimum 8-h fast, each subject received a
single oral 15-mg dose of cinacalcet (½ of a 30-mg tablet,
weighed with a Mettler balance) with 90 mL (3 oz) of water.
Subjects continued to fast for 4 h after treatment administra-
tion, and they were followed for 72 h after dosing.
Rationale for dosage selection
In vitro and in vivo studies have demonstrated that cinacalcet
is extensively metabolized by multiple cytochrome P450
(CYP) enzymes, including CYP3A4, CYP2D6, and CYP1A2
[18]. The capacity to metabolize drugs in children varies
throughout development of CYP enzymes and is completed
by approximately 6 years of age. Therefore, the difference in
pharmacokinetic properties of cinacalcet for adults and pedi-
atric patients older than 6 years is likely to be due to differ-
ences in body surface area (BSA). Based onBSA, a 6-year-old
child should receive approximately 50% of an adult dose. The
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recommended starting dose for cinacalcet in adults is 30 mg;
therefore, a dose of 15 mg was selected for this study.
Sample collection
Blood samples for safety assessments were collected at
screening, baseline, and on study Day 4. Blood samples for
pharmacokinetic analysis were collected at predose and at 0.5,
1, 2, 3, 4, 5, 6, 8, 12, 24, 48, and 72 h post-dose, and those for
pharmacodynamic (Ca and iPTH) analysis were obtained at
predose and at 2, 4, 8, 12, 24, 48, and 72 h post-dose.
Planned statistical analysis
All subjects who received cinacalcet were included in the
safety, pharmacokinetics, and pharmacodynamics analyses.
Since this was a descriptive study, the sample size of three
subjects per age-cohort was based on practical considera-
tions; no formal analyses for between-cohort comparisons
were conducted.
The safety profile assessment was based on adverse
events, vital signs, clinical laboratory measurements, elec-
trocardiogram, and physical examinations. An adverse event
was defined as an undesirable medical sign or symptom or
worsening of a pre-existing medical condition present at
baseline that occurred after initiation of the investigational
product. A serious adverse event included any event deemed
fatal or life threatening, an event that required or prolonged
in-patient hospitalization, or a persistent, significant disabil-
ity or incapacity, congenital anomaly, or birth defect, as well
as any event that may have resulted in urgent investigation.
Plasma cinacalcet concentration–time data were analyzed
by non-compartmental methods using WinNonlin Enterprise
(ver. 5.1.1; Pharsight Corp, Mountain View, CA). The serum
peak concentration (Cmax) after dosing was identified by
inspection of the data, and the corresponding time to reach
Cmax (tmax) was recorded. Plasma cinacalcet concentration
versus time was plotted on a semi-log-scale, and the data
points that described the terminal log-linear segment of the
elimination phase were identified. Whenever possible, a linear
regression of the log-transformed terminal data points versus
time was used to estimate the terminal rate constant β. The
terminal half-life, t1/sβ was calculated as 0.693/β. The area
under the concentration–time curve from zero to the last
measurable concentration (AUC0-t) was calculated by the
linear trapezoidal method. The AUC from the time of the last
measurable concentration to infinity (AUCt-inf) was calculated
by dividing the predicted concentration at the time of the last
measurable concentration by β. The AUC from time zero to
infinity, AUCo-inf, was calculated by the summation of AUC0-t
and AUCt-inf. AUC0-inf was not reported when AUCt-inf
exceeded 20 % of the total AUC. The apparent oral clearance
(CL/F) was calculated as dose/AUC0-inf.
Results
Study subjects
Table 1 shows the baseline demographics of the 12 pediatric
subjects with mean (SD) age of 11.3 (3.7) years receiving
chronic hemodialysis or peritoneal dialysis that were en-
rolled in this single dose study. All subjects were included
in all analysis sets.
Safety
Hypocalcemia (Ca <2.23 mmol/L), a documented effect of
cinacalcet in studies with adults, was reported in 50 % (n06)
of subjects, with a range of 2.00–2.22 mmol/L. Other
reported (n02, 17 %) adverse events were mild to moderate
in severity and assessed by the investigators to be unrelated to
the study drug. Bacteremia and pyrexia (with normal Ca
levels) were reported for one subject (age 11 years) 48
h post-dose. One subject (age 15 years) with a 6-month
history of ESRD had an adverse event of QT interval prolon-
gation within 72 h post-dose, which the investigator related to
prior trauma. Subsequent electrocardiograms performed 2
and 6 weeks after the date of onset showed a prolonged
QTc interval and non-specific ST segment changes. After
the 3-month follow-up visit the subject was referred to a
cardiologist who documented a normal QTc during assess-
ment. Based on the cardiologist’s report and the subject’s
negative family history for prolonged QT interval prolonga-
tion, the investigator considered the adverse event to be
unrelated to the investigational product. Neither of these
two subjects withdrew from the study due to the adverse
event, and they reported no serious adverse events.
Of the 12 subjects, six had decreases in serum Ca below
the lower limit of normal without any associated symptoms.
The low Ca values for these subjects ranged from 2.00 to
2.20 mmol/L up to 12 h post-dose. No clinically significant
trends were observed for the other serum chemistry, hema-
tology, or urinalysis laboratory assessments.
Table 1 Baseline demographics
Patient baseline demographics 15 mg cinacalcet (n012)
Female, n (%) 7 (58)
Hispanic or Latino, n (%) 6 (50)
Black or African American, n (%) 3 (25)
White or Caucasian, n (%) 3 (25)
Age (years), mean (SD) 11.33 (3.68)
Height (cm), mean (SD) 136.13 (20.53)
Weight (kg), mean (SD) 38.38 (15.67)
BMI (kg/m2), mean (SD) 19.85 (3.53)
BMI, Body mass index; SD, standard deviation
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Pharmacokinetics
Mean plasma cinacalcet concentration–time profiles by age-
cohort are presented in Fig. 1. For the four age cohorts (n03 in
each), namely, 6–8 years, 9–11 years, 12–14 years, and 15–
17 years, the values for the pharmacokinetic parameters were:
AUC0-t [h ng/mL; mean (SD)], 29.5 (15.6), 35.9 (35.8), 11.3
(4.4), and 17.5 (5.9), respectively; Cmax [mg/mL; mean (SD)],
11.0 (3.2), 9.19 (7.28), 3.87 (1.82), and 5.01 (2.15),
respectively; tmax [h; median (min–max)], 2.0 (2.0–2.0), 3.0
(2.0–4.0), 3.0 (1.0–3.0), and 3.0 (2.0–5.0), respectively. Age
and BSA versus AUC0-t , and age and BSA versus Cmax are
presented graphically in Figs. 2a, b and 3a, b, respectively.
Mean exposure (AUC0-t and Cmax) in the four age-
cohorts did not consistently increase with decreasing age.
Fig. 1 Mean plasma cinacalcet concentration–time profiles following
oral administration of 15-mg cinacalcet
Fig. 2 a Area under the time–concentration curve from zero to the last
measurable concentration (AUC0-t) by age for individual subjects. b
AUC0-t by body surface area (BSA) for all subjects. NS Not significant
Body Surface Area (m2)















Fig. 3 a Serum peak cinacelcet concentration (Cmax) by age for
individual subjects. b Cmax by BSA for individual subjects. NS Not
significant
Fig. 4 Mean serum calcium (Ca) concentrations by time for each
age-cohort. For all subjects, the mean ± standard deviation
maximum decrease was 4.3±6.0 % 8 h post-dose; Ca returned to
the baseline level by Day 2. The overall patterns of change from
baseline were similar for all age-cohorts
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However, a trend of greater exposure was observed in youn-
ger subjects as well as a trend of increasing exposure with
decreasing BSA. Values for AUC0-inf, t1/2β, and CL/F were
not calculable in most subjects.
Pharmacodynamics
Consistent with the pharmacologic action of cinacalcet,
mean (SD) percentage changes from baseline in serum Ca
(mmol/L) concentration were observed from 2 [−2.88
(5.40)] to 12 h [−2.93 (5.70)] post-dose; returning to base-
line levels by Day 2 (Fig. 4; Table 2). Mean (SD) percentage
changes in serum iPTH (pg/mL) concentrations decreased
−35.65 (55.82) from baseline values up to 2 h post-dose,
increased to above baseline between 4 [24.10 (76.14)] and
12 h [57.94 (71.82)] post-dose, and returned to baseline
levels by Day 2 (Fig. 5; Table 3). The observed patterns of
changes from baseline in mean serum Ca and iPTH concen-
trations was similar for each age cohort (Figs. 4, 5); the
small sample size per age-cohort precluded formal analysis.
Discussion
In this open-label study, we evaluated the safety, tolerability,
pharmacokinetics, and pharmacodynamics of a single, oral
15-mg dose of cinacalcet in pediatric subjects 6–17 years of
age with CKD who were on dialysis upon entry into the
study. No serious adverse events developed as a result of
hypocalcemia. All adverse events were mild to moderate in
severity. The adverse events reported by the two subjects,
bacteremia with pyrexia in one subject and a prolonged QTc
Table 2 Mean changes from
baseline over time in serum
calcium level for each
age-cohort
Data are presented as the mean,
with the standard deviation given
in parenthesis










Day 1, hour 2
Absolute (mmol/L) −0.09 (0.03) −0.14 (0.13) −0.10 (0.20) 0.03 (0.12) −0.07 (0.13)
Percentage −3.99 (1.47) −5.51 (4.63) −3.81 (7.58) 1.80 (5.76) −2.88 (5.40)
Day 1, hour 4
Absolute (mmol/L) −0.12 (0.07) −0.16 (0.16) −0.13 (0.20) 0.00 (0.26) −0.10 (0.17)
Percentage −5.13 (3.43) −6.13 (6.08) −5.18 (7.71) 0.78 (11.99) −3.92 (7.35)
Day 1, hour 8
Absolute (mmol/L) −0.07 (0.10) −0.21 (0.12) −0.07 (0.25) −0.09 (0.12) −0.11 (0.15)
Percentage −2.85 (4.36) −8.25 (4.46) −2.63 (10.13) −3.63 (5.28) −4.34 (6.04)
Day 1, hour 12
Absolute (mmol/L) −0.11 (0.09) −0.05 (0.20) −0.05 (0.22) −0.08 (0.10) −0.07 (0.14)
Percentage −4.63 (4.01) −1.73 (7.80) −1.98 (8.67) −3.37 (4.32) −2.93 (5.70)
Day 2
Absolute (mmol/L) 0.02 (0.02) 0.02 (0.14) −0.02 (0.25) 0.15 (0.09) 0.05 (0.14)
Percentage 1.12 (1.14) 1.22 (5.51) −0.54 (9.86) 6.74 (4.60) 2.13 (5.96)
Day 3
Absolute (mmol/L) 0.08 (0.08) 0.02 (0.18) −0.05 (0.19) 0.09 (0.10) 0.04 (0.14)
Percentage 3.72 (3.45) 1.29 (7.10) −1.86 (7.30) 3.97 (4.37) 1.78 (5.52)
End of study
Absolute (mmol/L) 0.05 (0.10) 0.02 (0.32) 0.01 (0.18) 0.14 (0.13) 0.05 (0.18)
Percentage 2.26 (4.27) 1.19 (12.54) 0.55 (7.10) 6.42 (6.23) 2.60 (7.34)
Fig. 5 Mean serum intact parathyroid hormone (iPTH) concentrations
by time for each age-cohort. Maximum mean ± standard deviation
decrease was 35.7±55.8 % at 2 h post-dose; PTH returned to baseline
level by Day 2. The observed patterns of change from baseline were
similar for each age-cohort
Pediatr Nephrol (2012) 27:1953–1959 1957
interval in the second subject, were considered by the inves-
tigators to be unrelated to treatment with cinacalcet. Overall,
cinacalcet was well tolerated.
The mean pharmacokinetics exposure did not consistent-
ly increase with decreasing age; however, an overall trend of
greater exposure in younger subjects was observed, which
may be related to the lower body weight and BSA in
younger subjects compared with older subjects. The mean
AUC0-t and Cmax values following a single 15-mg dose of
cinacalcet for the combined cohorts in this study were
within approximately 30 % of values observed following a
single 30-mg dose (one 30-mg tablet) of cinacalcet admin-
istered to healthy adult subjects in a previous study (Amgen
study 20060133; data on file).
The patterns of changes in serum Ca and iPTH concen-
tration from baseline were similar between cohorts and
within the expected ranges for patients with CKD. These
findings are consistent with published data, which demon-
strate a reduction in plasma iPTH levels as well as serum Ca
and phosphorus levels for adult patients on hemodialysis
following the administration of cinacalcet [5, 8, 19, 20].
Furthermore, results from small observational studies sug-
gest that the administration of cinacalcet when PTH levels
are between 300–500 pg/mL or 501–800 pg/mL decreases
PTH to <300 pg/mL within 16–28 weeks of therapy [11]
(Amgen; data on file). Achieving therapeutic target ranges is
important in decreasing the risk of other bone and mineral
comorbidities associated with sHPT that when left untreated
can lead to increased rates of hospitalization.
Although in combination with PTH level dialysis vintage
may affect biochemical responses to cinacalcet, Padhi et al.
previously reported that the use of dialysis (hemodialysis
and peritoneal dialysis) does not affect the pharmacokinetics
or pharmacodynamics of cinacalcet, as it is a lipophilic drug
that is approximately 96 % protein bound and not dialyzable
[21]. Their study showed that baseline PTH levels increased
with decreased renal function, while changes in Ca were not
consistent from baseline to nadir and at peak concentrations.
Table 3 Mean changes from
baseline over time in serum
intact parathyroid hormone
level for each age-cohort
Data are presented as the mean,
with the standard deviation given
in parenthesis

















−59.33 (42.36) 16.00 (47.57) −104.17
(135.92)
Percentage −63.83 (9.35) −14.03 (99.53) −55.26 (20.34) −9.49 (56.84) −35.65 (55.82)





−85.67 (95.47) 77.67 (87.64) 81.67 (151.96) 3.67 (124.61)
Percentage 9.09 (66.66) −20.76 (45.04) 80.76 (101.55) 27.32 (83.12) 24.10 (76.14)
Day 1, hour 8
Absolute
(pg/mL)
−11.00 (89.40) 55.33 (47.65) 76.67 (76.96) 26.33 (29.19) 36.83 (65.41)
Percentage 10.36 (29.83) 79.50 (104.36) 66.84 (70.91) 42.44 (26.78) 49.78 (62.81)
Day 1, hour 12
Absolute
(pg/mL)
−6.33 (87.32) 51.33 (69.87) 56.33 (92.64) 49.00 (57.19) 37.58 (71.68)








−28.00 (4.58) −38.00 (65.05) −57.50
(101.33)






−41.00 (47.79) −23.33 (11.02) 1.67 (7.23) −30.92 (58.22)






16.00 (35.34) −6.00 (15.87) −32.00 (87.42)
Percentage −7.45 (17.58) 211.79
(457.53)
16.38 (41.31) 9.58 (26.94) 57.58 (217.46)
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Therefore, the dose in the present study, based primarily on
the BSA of subjects, was appropriately determined and did
not need further modification based on dialysis.
These data are important since they provide the first formal
pharmacokinetic and pharmacodynamic data related to the use
of cinacalcet in children and support further investigation of
cinacalcet to establish the appropriate starting dose for the
treatment of sHPT in pediatric patients receiving dialysis.
These data will now serve as the basis for determining drug
dosing in prospective clinical trials designed to evaluate the
safety and efficacy of cinacalcet in the pediatric dialysis
population with sHPT.
Limitations of current study
This was a small, open-label study to evaluate the safety and
describe the administration of a single-dose of cinacalcet in
pediatric dialysis patients with sHPT. Due to the sample size
no formal statistical comparisons were made in this study.
Dialysis vintage was not collected; however, it was reportedly
brief compared to adults since most pediatric patients are
transplanted or return from transplant. Although the results
from our study are consistent with observations in adults from
the same population, the current analysis precludes drawing
strong conclusions at this time. However, future studies of
pediatric patients with a larger sample size will likely yield
comparable results to the adult population.
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